Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA
New funding led by Goldcrest Capital and Godfrey Capital to advance lead candidate JUN_01 for type 2 diabetes and obesity to first-in-human studies JUN_01 would be the first ever candidate to reprogram metabolism with siRNA,…
